ICU Medical (ICUI) AI Stock Analysis

• Market Cap: $3.10B
• Dividend Yield: N/A
• Average Volume (3M): 270.30K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.77
• Revenue Growth: 2.95%
• EPS Growth: 47.92%
• Country: US
• Employees: 15,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 2.03
• Shares Outstanding: 24,685,715
• 10 Day Avg. Volume: 234,095
• 30 Day Avg. Volume: 270,295
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.41
• Enterprise Value/Revenue: 1.84
• Enterprise Value/Gross Profit: 5.14
• Enterprise Value/Ebitda: 13.39
• 1Y Price Target: $176.00
• Price Target Upside: 35.73% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 58 Neutral
• Price Target: $135.00 ▲(4.11% Upside)

ICU Medical's overall stock score is driven by a positive earnings call that highlights revenue growth and improved guidance, which offsets some of the financial performance challenges. Technical analysis shows bullish momentum, but valuation remains a concern due to negative profitability metrics. The absence of corporate events and dividend yield further impacts the score.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong market demand and effective business strategies, supporting long-term expansion and stability.

Debt Management

Effective debt management enhances financial flexibility and reduces interest burden, contributing to long-term financial health.

Product Innovation

Continued innovation and regulatory engagement ensure competitive positioning and future revenue streams through new product offerings.

Negative Factors

Profitability Challenges

Negative profit margins highlight difficulties in cost management and pricing power, which can hinder long-term financial performance.

Cash Flow Issues

Weak cash flow generation limits the company's ability to invest in growth opportunities and manage financial obligations effectively.

Tariff Impact

Tariff expenses increase operational costs and pressure margins, potentially affecting competitiveness and profitability in the long term.

ICU Medical Business Overview & Revenue Model

Company Description

ICU Medical, Inc. (ICUI) is a global medical technology company that specializes in the development, manufacturing, and sale of innovative medical devices used in infusion therapy, oncology, and critical care. The company primarily operates in the healthcare sector, offering a range of products that include infusion systems, intravenous (IV) access devices, and other related solutions designed to improve patient safety and outcomes. ICU Medical is well-known for its advanced technologies that help healthcare providers deliver medications and fluids accurately and safely.

How the Company Makes Money

ICU Medical generates revenue primarily through the sale of its medical devices and systems. Key revenue streams include the sale of infusion systems, IV access devices, and related consumables. The company also earns income from service agreements and maintenance contracts for its products. Significant partnerships with healthcare providers and hospitals enhance its market reach, while ongoing investments in research and development allow ICU Medical to innovate and expand its product offerings, further driving revenue growth. Additionally, the company benefits from a global presence, enabling it to tap into various international markets.

ICU Medical Financial Statement Overview

Summary

ICU Medical's financial performance is challenged by negative net income and declining free cash flow. Despite improvements in operational efficiency and leverage management, profitability issues persist, impacting overall financial stability.

Income Statement

ICU Medical's income statement shows a declining trend in revenue growth with a negative growth rate of -1.97% in the TTM period. The gross profit margin has slightly improved to 35.84% from the previous year, but the net profit margin remains negative at -1.56%, indicating ongoing profitability challenges. The EBIT and EBITDA margins have improved to 5.00% and 13.76% respectively, showing some operational efficiency gains. However, the overall profitability remains weak due to negative net income.

Balance Sheet

The balance sheet reflects a moderate debt-to-equity ratio of 0.66, which has improved from the previous year, indicating better leverage management. However, the return on equity is negative at -1.82%, highlighting challenges in generating returns for shareholders. The equity ratio stands at 51.51%, suggesting a stable capital structure with a reasonable proportion of equity financing.

Cash Flow

Cash flow analysis reveals a significant decline in free cash flow growth by -53.72% in the TTM period, indicating cash generation issues. The operating cash flow to net income ratio is 0.29, suggesting that operating cash flows are not sufficient to cover net losses. The free cash flow to net income ratio is 0.44, reflecting some ability to generate cash relative to net income, but overall cash flow performance remains weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.37B	2.38B	2.26B	2.28B	1.32B	1.27B
Gross Profit	850.28M	824.78M	739.87M	697.76M	491.49M	461.50M
EBITDA	326.34M	42.96M	253.20M	231.58M	223.46M	194.09M
Net Income	-36.95M	-117.69M	-29.66M	-74.29M	103.14M	86.87M
Balance Sheet
Total Assets	4.11B	4.20B	4.38B	4.52B	1.88B	1.76B
Cash, Cash Equivalents and Short-Term Investments	300.02M	308.57M	254.72M	213.01M	567.25M	410.78M
Total Debt	1.39B	1.64B	1.70B	1.73B	45.69M	52.70M
Total Liabilities	1.99B	2.24B	2.26B	2.43B	264.71M	261.43M
Stockholders Equity	2.12B	1.97B	2.12B	2.09B	1.62B	1.50B
Cash Flow
Free Cash Flow	61.06M	124.66M	72.53M	-161.46M	186.37M	122.36M
Operating Cash Flow	138.83M	204.03M	166.20M	-62.13M	267.54M	222.75M
Investing Cash Flow	121.24M	-88.96M	-87.95M	-1.91B	-90.69M	-98.14M
Financing Cash Flow	-269.92M	-55.80M	-35.98M	1.64B	-16.87M	-40.00K

ICU Medical Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 129.67
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ICUI, the sentiment is Positive. The current price of 129.67 is above the 20-day moving average (MA) of 120.54, above the 50-day MA of 123.86, and below the 200-day MA of 134.84, indicating a neutral trend. The MACD of 1.06 indicates Negative momentum. The RSI at 64.59 is Neutral, neither overbought nor oversold. The STOCH value of 88.95 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ICUI.

ICU Medical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
COO	72 Outperform	$13.69B	33.97	5.01%	―	6.35%	12.94%
BDX	70 Outperform	$50.56B	31.72	6.26%	2.35%	7.86%	14.24%
HOLX	69 Neutral	$16.52B	29.86	11.12%	―	1.74%	-25.29%
ICUI	58 Neutral	$3.10B	-82.51	-1.78%	―	2.95%	47.92%
BAX	53 Neutral	$9.22B	―	-4.70%	3.78%	-21.20%	-325.40%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ATR	50 Neutral	$7.58B	18.52	15.80%	1.58%	2.50%	25.05%

ICU Medical Corporate Events

ICU Medical Reports Q3 2025 Earnings and Updates Guidance

ICU Medical, Inc. is a global leader in the development and sale of infusion systems, consumables, and critical care products, catering to hospital and home care settings. Headquartered in San Clemente, California, the company is known for its focus on quality and innovation in the medical products sector.

ICU Medical’s Earnings Call: Stability Amid Tariff Challenges

The latest earnings call from ICU Medical presented a balanced sentiment, highlighting stable revenue performance alongside notable growth in consumables and IV systems. However, the company faces significant challenges due to increased tariffs impacting profitability, prompting adjusted guidance. Despite these hurdles, ICU Medical remains committed to mitigating these impacts while continuing to invest in innovation and infrastructure improvements.

ICU Medical Reports Improved Profitability in Q2 2025

ICU Medical, Inc. is a global leader in the development, manufacture, and sale of innovative medical products, primarily focusing on infusion systems, infusion consumables, and critical care products for hospital and home care settings. Headquartered in San Clemente, California, the company is known for its commitment to quality, innovation, and value.